Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HK2 | P52789 | 5/20 | 0.43 |
| ▸ | HK1 | P19367 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.41 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.41 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.41 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.41 |
| ▸ | PYGB | P11216 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
| ▸ | HEXB | P07686 | 1/20 | 0.39 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12221751 | 1.00 | KDM4E (0.51) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL12580215 | 1.00 | KDM4E (0.51) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL17179624 | 1.00 | KDM4E (0.51) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL18542677 | 1.00 | KDM4E (0.51) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL13026570 | 1.00 | KDM4E (0.51) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL18542696 | 1.00 | KDM4E (0.51) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL18819836 | 1.00 | KDM4E (0.51) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL16328380 | 1.00 | KDM4E (0.51) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL18972932 | 1.00 | KDM4E (0.51) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL14164184 | 1.00 | KDM4E (0.51) | KDM4ELMNACYP2D6CYP2C19HK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403857-B2 | Compositions and methods for the treatment of metabolic syndrome | CELLIX BIO PRIVATE LIMITED (IN) | 2016-08-02 | — | — | US | disclosed |
| US-9321716-B1 | Compositions and methods for the treatment of metabolic syndrome | CELLIX BIO PRIVATE LIMITED (IN) | 2016-04-26 | — | — | US | disclosed |
| US-9315478-B2 | Compositions and methods for the treatment of metabolic syndrome | CELLIX BIO PRIVATE LIMITED (IN) | 2016-04-19 | — | — | US | disclosed |
| US-20150126497-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME | CELLIX BIO PRIVATE LIMITED (IN) | 2015-05-07 | — | — | US | disclosed |
| US-20150080345-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME | CELLIX BIO PRIVATE LIMITED (IN) | 2015-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080345-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME | FABP4, GYS2, FABP2 | KDM4E 4754/4885LMNA 2634/4885CYP2D6 289/4885 |
| US-20150126497-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME | SLC5A1, IRS1, SLC5A2 | KDM4E 4727/4885LMNA 698/4885CYP2D6 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.